Cell
lysis is the first step of protein extraction, which is further used
for different application such as enzyme engineering and protein
labelling. Furthermore, cell lysis is also an important step to study
protein -protein interaction, which supports growth of cell lysis
market. Players in the global cell lysis market are focusing on
investing in R&D, to introduce advanced products used in cell
lysis process. Furthermore, increasing demand for cell-based therapy
for treatment purpose of cancer is also expected to augment growth of
the cell lysis market. For instance, in 2017, US-based manufacturers
Zymo Research Corp. and Bertin Technologies collaborated to develop
real-time sample lysis step, which is carried out only in one minute.
The
global cell lysis market was valued at US$ 2,715.1 billion in 2017
and is expected to witness a CAGR of 8.6 % over the forecast period
(2017–2025).
Free
Request Sample of Report:
https://www.coherentmarketinsights.com/insight/request-sample/741
Robust
research and development is expected to Drive Growth of the Cell
Lysis Market
Increasing
research and development in the field of proteomics and genomics and
high prevalence of infectious disease and cancer are the major
factors driving growth of the cell lysis market. For instance,
According to 2012 EU Industrial R&D Investment Scoreboard, the
pharmaceutical and biotechnology sectors represented 17.7% of
business R&D expenditure in the world. Furthermore, in 2017, the
FDA approved 2 CAR-T cell therapy for the treatment of patients up to
25 years of age with B-cell precursor acute lymphoblastic leukemia
and adult patients with certain types of large B-cell lymphoma. Such
advancement in cell-based therapy support the growth of cell lysis
market. However, high cost of cell based research, owing to high
expenditure in research and development for CAR-T cell therapy may
hamper the growth of the market as The FDA approved CAR T-Cell
therapy is priced at US$ 475,000 for single infusion for pediatric
and young adult patients with B-cell precursor acute lymphoblastic
leukemia. Moreover, this cost does not include pre-infusion treatment
cost, drug administration, hospitalization costs, and costs
associated with adverse events and follow-up care
Increase
in Prevalence of Cancer Cases is also Driving Growth of the Cell
Lysis Market
Rise
in prevalence of infectious disease and cancer cases in various
regions of the world leads to more utilization of cell samples for
research and development of drugs thus, expected to have a meteoric
growth for the cell lysis market. For instance, According to the
estimates by GLOBOCAN 2012, an estimated 850,000 new cancer cases
were diagnosed in Africa, while almost 600,000 deaths were attributed
to malignant disease. The number of cancer cases is expected to rise
to 1,056,000 by 2020. Furthermore, According to the World Health
Organization (WHO), in 2012, around 3,319 deaths occurred due to the
infectious and parasitic disease infection, in Sub Saharan Africa
region and according to the same source, in 2014, Ebola accounted
around 8,000 deaths in this region.
Key
Players
Major
Key players involved in cell lysis market includes: Thermo Fisher
Scientific Inc., Merck & Co. Inc., Qiagen N.V., F. Hoffmann-La
Roche Ltd, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc.,
Cell Signaling Technology, Inc., and Qsonica.
Detailed
Segmentation:
Global
Cell Lysis Market, By Product Type:
-
Instruments
-
Consumables
Global
Cell Lysis Market, By Cell Type:
-
Mammalian Cells
-
Microbial Cells
-
Other Cells
Find
the comprehensive research report here with a single click:
https://www.coherentmarketinsights.com/market-insight/cell-lysis-market-741
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm
offering action-ready syndicated research reports, custom market
analysis, consulting services, and competitive analysis through
various recommendations related to emerging market trends,
technologies, and potential absolute dollar opportunity.
Contact
Us:
Mr.
Shah
Coherent
Market Insights
1001
4th Ave,
#3200
Seattle,
WA 98154
Tel:
+1-206-701-6702
